目的探讨microRNA-16(miR-16)在急性缺血性脑卒中(acute ischemic stroke,AIS)中表达水平及其对预后的影响。方法选取辽阳市中心医院神经内科2016年1月-2020年1月收治的279例AIS患者(AIS组)作为研究对象,治疗结束后3个月,采用改良Ranki...目的探讨microRNA-16(miR-16)在急性缺血性脑卒中(acute ischemic stroke,AIS)中表达水平及其对预后的影响。方法选取辽阳市中心医院神经内科2016年1月-2020年1月收治的279例AIS患者(AIS组)作为研究对象,治疗结束后3个月,采用改良Rankin量表(modified rankin scale,MRS)评价患者预后,根据预后情况将患者分为预后良好组(196例)和预后不良组(83例)。另选取114例在本院例行体检的健康者作为健康组。采用实时荧光定量PCR(quantitative real-time PCR,qRT-PCR)检测血清中miR-16含量。比较AIS组和健康组外周血miR-16表达水平;比较预后不良组和预后良好组患者一般临床资料及生化指标;多因素Logistic回归分析预后不良的危险因素;受试者工作特征曲线(receiver operating characteristic curve,ROC)分析外周血miR-16表达水平对AIS预后不良的预测价值。结果AIS组外周血miR-16、miR-135b表达水平显著高于健康组(P<0.05);预后不良组患者年龄,糖尿病史率,外周血中miR-16、miR-135b表达水平,MRS评分,美国国立卫生研究院卒中量表(National Institute of Health stroke scale,NIHSS)评分均显著高于预后良好组(均P<0.05);年龄、糖尿病史、miR-16、miR-135b、MRS、NIHSS评分为AIS患者预后不良的影响因素(均P<0.05);miR-16、miR-135b、miR-16联合miR-135b预测AIS预后不良的曲线下面积(area under the curve,AUC)分别为0.739(95%CI=0.676~0.801)、0.704(95%CI=0.638~0.770),0.802(95%CI=0.745~0.859);miR-16联合miR-135b预测AIS预后不良的AUC大于miR-16、miR-135b的AUC(P<0.05)。结论miR-16在AIS中表达水平升高,升高预示患者预后不良,可作为预测AIS预后不良的标志物,且miR-16联合miR 135b对AIS患者预后不良的测价值高于单独miR-16、miR-135b。展开更多
Wu et al recently applied multi-region 16S rRNA sequencing to characterize the gastric cancer microbiome,demonstrating improved taxonomic resolution and detection sensitivity over conventional single-region approaches...Wu et al recently applied multi-region 16S rRNA sequencing to characterize the gastric cancer microbiome,demonstrating improved taxonomic resolution and detection sensitivity over conventional single-region approaches.While the study represents a valuable methodological step forward,it remains limited by singlecenter design,lack of quantitative calibration,and insufficient control for contamination and inter-laboratory variability.This editorial critically appraises these methodological gaps and emphasizes that future efforts must focus on harmonized,consensus-driven workflows to ensure reproducibility and clinical reliability.The translational potential of multi-region 16S lies in moving from descriptive microbial profiling to actionable clinical integration,particularly for recurrence prediction,treatment-response monitoring,and perioperative complication risk assessment.By addressing these methodological,economic,and ethical challenges,the field can advance toward evidence-based and clinically deployable microbiome-guided precision oncology.展开更多
文摘目的探讨microRNA-16(miR-16)在急性缺血性脑卒中(acute ischemic stroke,AIS)中表达水平及其对预后的影响。方法选取辽阳市中心医院神经内科2016年1月-2020年1月收治的279例AIS患者(AIS组)作为研究对象,治疗结束后3个月,采用改良Rankin量表(modified rankin scale,MRS)评价患者预后,根据预后情况将患者分为预后良好组(196例)和预后不良组(83例)。另选取114例在本院例行体检的健康者作为健康组。采用实时荧光定量PCR(quantitative real-time PCR,qRT-PCR)检测血清中miR-16含量。比较AIS组和健康组外周血miR-16表达水平;比较预后不良组和预后良好组患者一般临床资料及生化指标;多因素Logistic回归分析预后不良的危险因素;受试者工作特征曲线(receiver operating characteristic curve,ROC)分析外周血miR-16表达水平对AIS预后不良的预测价值。结果AIS组外周血miR-16、miR-135b表达水平显著高于健康组(P<0.05);预后不良组患者年龄,糖尿病史率,外周血中miR-16、miR-135b表达水平,MRS评分,美国国立卫生研究院卒中量表(National Institute of Health stroke scale,NIHSS)评分均显著高于预后良好组(均P<0.05);年龄、糖尿病史、miR-16、miR-135b、MRS、NIHSS评分为AIS患者预后不良的影响因素(均P<0.05);miR-16、miR-135b、miR-16联合miR-135b预测AIS预后不良的曲线下面积(area under the curve,AUC)分别为0.739(95%CI=0.676~0.801)、0.704(95%CI=0.638~0.770),0.802(95%CI=0.745~0.859);miR-16联合miR-135b预测AIS预后不良的AUC大于miR-16、miR-135b的AUC(P<0.05)。结论miR-16在AIS中表达水平升高,升高预示患者预后不良,可作为预测AIS预后不良的标志物,且miR-16联合miR 135b对AIS患者预后不良的测价值高于单独miR-16、miR-135b。
文摘Wu et al recently applied multi-region 16S rRNA sequencing to characterize the gastric cancer microbiome,demonstrating improved taxonomic resolution and detection sensitivity over conventional single-region approaches.While the study represents a valuable methodological step forward,it remains limited by singlecenter design,lack of quantitative calibration,and insufficient control for contamination and inter-laboratory variability.This editorial critically appraises these methodological gaps and emphasizes that future efforts must focus on harmonized,consensus-driven workflows to ensure reproducibility and clinical reliability.The translational potential of multi-region 16S lies in moving from descriptive microbial profiling to actionable clinical integration,particularly for recurrence prediction,treatment-response monitoring,and perioperative complication risk assessment.By addressing these methodological,economic,and ethical challenges,the field can advance toward evidence-based and clinically deployable microbiome-guided precision oncology.
